Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Co-Targeting of JNK and HUNK in Resistant HER2-Positive Breast Cancer.

Phelps-Polirer K, Abt MA, Smith D, Yeh ES.

PLoS One. 2016 Apr 5;11(4):e0153025. doi: 10.1371/journal.pone.0153025. eCollection 2016.

2.

Recurrent MLK4 Loss-of-Function Mutations Suppress JNK Signaling to Promote Colon Tumorigenesis.

Marusiak AA, Stephenson NL, Baik H, Trotter EW, Li Y, Blyth K, Mason S, Chapman P, Puto LA, Read JA, Brassington C, Pollard HK, Phillips C, Green I, Overman R, Collier M, Testoni E, Miller CJ, Hunter T, Sansom OJ, Brognard J.

Cancer Res. 2016 Feb 1;76(3):724-35. doi: 10.1158/0008-5472.CAN-15-0701-T. Epub 2015 Dec 4.

3.
4.

In vivo gene manipulation reveals the impact of stress-responsive MAPK pathways on tumor progression.

Kamiyama M, Naguro I, Ichijo H.

Cancer Sci. 2015 Jul;106(7):785-96. doi: 10.1111/cas.12676. Epub 2015 May 25. Review.

5.

Impaired JNK signaling cooperates with KrasG12D expression to accelerate pancreatic ductal adenocarcinoma.

Davies CC, Harvey E, McMahon RF, Finegan KG, Connor F, Davis RJ, Tuveson DA, Tournier C.

Cancer Res. 2014 Jun 15;74(12):3344-56. doi: 10.1158/0008-5472.CAN-13-2941. Epub 2014 Apr 8.

6.

Stress signaling and the shaping of the mammary tissue in development and cancer.

Avivar-Valderas A, Wen HC, Aguirre-Ghiso JA.

Oncogene. 2014 Nov 27;33(48):5483-90. doi: 10.1038/onc.2013.554. Epub 2014 Jan 13. Review.

7.

The 2 Faces of JNK Signaling in Cancer.

Tournier C.

Genes Cancer. 2013 Sep;4(9-10):397-400. doi: 10.1177/1947601913486349. Review.

8.

BRAF inhibitors suppress apoptosis through off-target inhibition of JNK signaling.

Vin H, Ojeda SS, Ching G, Leung ML, Chitsazzadeh V, Dwyer DW, Adelmann CH, Restrepo M, Richards KN, Stewart LR, Du L, Ferguson SB, Chakravarti D, Ehrenreiter K, Baccarini M, Ruggieri R, Curry JL, Kim KB, Ciurea AM, Duvic M, Prieto VG, Ullrich SE, Dalby KN, Flores ER, Tsai KY.

Elife. 2013 Nov 5;2:e00969. doi: 10.7554/eLife.00969.

9.

JNK signalling in cancer: in need of new, smarter therapeutic targets.

Bubici C, Papa S.

Br J Pharmacol. 2014 Jan;171(1):24-37. doi: 10.1111/bph.12432. Review.

10.

Mechanisms that link the oncogenic epithelial-mesenchymal transition to suppression of anoikis.

Frisch SM, Schaller M, Cieply B.

J Cell Sci. 2013 Jan 1;126(Pt 1):21-9. doi: 10.1242/jcs.120907. Review.

11.

Klf4 is a transcriptional regulator of genes critical for EMT, including Jnk1 (Mapk8).

Tiwari N, Meyer-Schaller N, Arnold P, Antoniadis H, Pachkov M, van Nimwegen E, Christofori G.

PLoS One. 2013;8(2):e57329. doi: 10.1371/journal.pone.0057329. Epub 2013 Feb 25. Erratum in: PLoS One. 2013;8(10). doi:10.1371/annotation/121b04a1-0cbb-4e24-8a63-fc9cdd31ec76.

12.

Inflammation- and stress-related signaling pathways in hepatocarcinogenesis.

Nakagawa H, Maeda S.

World J Gastroenterol. 2012 Aug 21;18(31):4071-81. doi: 10.3748/wjg.v18.i31.4071. Review.

13.

JNK and PTEN cooperatively control the development of invasive adenocarcinoma of the prostate.

Hübner A, Mulholland DJ, Standen CL, Karasarides M, Cavanagh-Kyros J, Barrett T, Chi H, Greiner DL, Tournier C, Sawyers CL, Flavell RA, Wu H, Davis RJ.

Proc Natl Acad Sci U S A. 2012 Jul 24;109(30):12046-51. doi: 10.1073/pnas.1209660109. Epub 2012 Jul 2.

14.

Molecular mechanisms of liver injury and hepatocarcinogenesis: focusing on the role of stress-activated MAPK.

Nakagawa H, Maeda S.

Patholog Res Int. 2012;2012:172894. doi: 10.1155/2012/172894. Epub 2012 May 14.

15.

Role of JNK in mammary gland development and breast cancer.

Cellurale C, Girnius N, Jiang F, Cavanagh-Kyros J, Lu S, Garlick DS, Mercurio AM, Davis RJ.

Cancer Res. 2012 Jan 15;72(2):472-81. doi: 10.1158/0008-5472.CAN-11-1628. Epub 2011 Nov 29.

16.

Cdc42 and Rac1 are major contributors to the saturated fatty acid-stimulated JNK pathway in hepatocytes.

Sharma M, Urano F, Jaeschke A.

J Hepatol. 2012 Jan;56(1):192-8. doi: 10.1016/j.jhep.2011.03.019. Epub 2011 May 18.

Items per page

Supplemental Content

Write to the Help Desk